文献速递泌尿男性生殖肿瘤

血浆AR状态与卡巴他赛治疗经治转移性去势抵抗性前列腺癌

Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer.
PubMed 文献 · Eur J Cancer · 2019-06-11

该研究纳入155例接受二线或三线卡巴他赛治疗的mCRPC患者,采用微滴数字PCR检测血浆AR拷贝数。AR增益患者较AR正常患者PFS显著缩短(4.0 vs 5.0个月,HR=1.47,P=0.024),OS有缩短趋势但未达统计学显著(10.5 vs 14.1个月,HR=1.44,P=0.064)。探索性分析提示血浆AR状态与治疗类型对OS存在交互作用。

要点

  • 血浆AR增益与卡巴他赛治疗后PFS显著缩短相关(HR=1.47,P=0.024)。
  • AR增益患者OS有缩短趋势但未达统计学显著(HR=1.44,P=0.064)。
  • 探索性分析中AR增益患者接受初始减量卡巴他赛OS和PFS均显著更短。

核心结论

  • 血浆AR状态对考虑使用卡巴他赛的mCRPC患者具有潜在临床价值,但需前瞻性试验验证。

研究设计与样本

  • 2011年9月至2018年1月收集155例接受二线或三线卡巴他赛治疗(标准或减量)的mCRPC患者治疗前血浆样本,用微滴数字PCR检测血浆AR增益与正常。

主要发现

  • AR增益患者较AR正常患者中位OS为10.5 vs 14.1个月(HR=1.44,95%CI 0.98-2.13,P=0.064)。
  • AR增益患者较AR正常患者中位PFS为4.0 vs 5.0个月(HR=1.47,95%CI 1.05-2.07,P=0.024)。
  • 二线治疗患者中血浆AR与卡巴他赛对比AR靶向治疗对OS存在显著交互作用(P=0.041),对PFS无显著交互作用(P=0.244)。
  • 探索性分析中AR增益患者接受初始减量卡巴他赛中位OS为7.3 vs 11.5个月(HR=1.95,95%CI 1.13-3.38,P=0.016)。
  • 探索性分析中AR增益患者接受初始减量卡巴他赛中位PFS为2.7 vs 5.0个月(HR=2.27,95%CI 1.39-3.71,P=0.001)。

临床怎么用

  • 在考虑卡巴他赛治疗的mCRPC患者中,可检测血浆AR拷贝数状态以辅助预后评估。

局限性

  • 研究为回顾性样本分析,结论需前瞻性试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasma androgen receptor (AR) copy number status has been identified as a potential biomarker of response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel or the AR-targeted therapies abiraterone or enzalutamide. However, the relevance of plasma AR status in the context of cabazitaxel therapy is unknown. PATIENTS AND METHODS: Between September 2011 and January 2018, pretherapy plasma samples were collected from 155 patients treated with second- or third-line cabazitaxel at standard or reduced dose in different biomarker protocols. Droplet digital polymerase chain reaction was used to identify plasma AR gain and normal samples. The primary objective was to evaluate associations of plasma AR status with treatment outcome. In an exploratory analysis, a comparison between plasma AR and treatment type was investigated by incorporating updated data from our prior study of 85 post-docetaxel patients receiving abiraterone or enzalutamide. RESULTS: We observed a shorter median overall survival (OS) and progression-free survival (PFS) in AR-gained compared to AR-normal patients (OS 10.5 versus 14.1 months, hazard ratio (HR) = 1.44, 95% confidence interval [CI] 0.98-2.13, P = 0.064 and PFS 4.0 versus 5.0 months, HR = 1.47, 95% CI 1.05-2.07, P = 0.024). In patients with mCRPC receiving second-line therapies, a significant treatment interaction was observed between plasma AR and cabazitaxel versus AR-directed therapies for OS (P = 0.041) but not PFS (P = 0.244). In an exploratory analysis, AR-gained patients treated with initial reduced dose of cabazitaxel had a significantly shorter median OS (7.3 versus 11.5 months, HR = 1.95, 95% CI 1.13-3.38, P = 0.016) and PFS (2.7 versus 5.0 months, HR = 2.27, 95% CI 1.39-3.71, P = 0.001). CONCLUSION: Plasma AR status has a potential clinical utility in patients being considered for cabazitaxel. Validation of these findings in prospective trials is warranted.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Conteduca V, Castro E, Wetterskog D, et al. Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. Eur J Cancer. 2019. PMID: 31200322. doi:10.1016/j.ejca.2019.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。